Fennec Pharma CMO granted 120,000 stock options
Sayad Pierre Sargis reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
Sayad Pierre Sargis reported acquisition or exercise transactions in this Form 4 filing.
FENNEC PHARMACEUTICALS INC. Chief Medical Officer Pierre Sargis Sayad reported equity compensation activity. On March 31, 2026, he received incentive stock options for 120,000 common shares at $5.77 per share, expiring March 31, 2036, under the 2020 Equity Incentive Plan.
One-third of these options vest on March 31, 2027, with additional vesting monthly until fully vested by March 31, 2029. The filing also shows settlement of performance share units and release of restricted shares, bringing direct holdings to 20,679 common shares. All transactions reflect awards and vesting rather than open‑market trading.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Sayad Pierre Sargis
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 120,000 | $5.77 | $692K |
| Exercise | Common Shares | 18,456 | $0.00 | $0.00 |
| Exercise | Common shares | 171 | $0.00 | $0.00 |
| Exercise | Common shares | 2,052 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options — 270,000 contracts (Direct);
Common shares — 18,627 shares (Direct)
Footnotes (4)
- F1. Represents settlement of PSUs that vested on March 31, 2026.
- F2. Represents shares released from restriction from shares awarded 3/28/2025.
- F3. On March 31, 2026, granted incentive stock options to purchase 120,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan.
- F4. One-third of the shares subject to this option may be exercised as of March 31, 2027 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this option shall vest and may be exercised as of the last day of each month following the Vesting Commencement Date. As of March 31, 2029, 100% of the total number of shares subject to this option shall be vested.
Key Figures
Stock options granted: 120,000 options at $5.77
Options expiration: March 31, 2036
Initial option vesting: One-third on March 31, 2027
+4 more
7 metrics
Stock options granted
120,000 options at $5.77
Incentive stock options granted March 31, 2026
Options expiration
March 31, 2036
Expiration date of 120,000 incentive stock options
Initial option vesting
One-third on March 31, 2027
First vesting tranche for stock options
Full vesting date
March 31, 2029
Date when 100% of option shares are vested
PSU settlement shares
18,456 shares
Performance share units vested and settled March 31, 2026
Restricted shares released
2,052 shares
Shares released from restriction from March 28, 2025 award
Common shares held
20,679 shares
Direct common share holdings after March 28–31, 2026 transactions
Key Terms
incentive stock options, PSUs, 2020 Equity Incentive Plan, vested, +1 more
5 terms
incentive stock options financial
"On March 31, 2026, granted incentive stock options to purchase 120,000 shares"
Incentive stock options are a type of employee stock option that gives eligible workers the right to buy company shares at a fixed price later on, often below future market value. They matter to investors because they align employee incentives with company performance, can dilute existing ownership when exercised, and create potential tax advantages for option holders if certain holding-time rules are met — think of them as a coupon to buy stock at today’s price with extra tax rules attached.
PSUs financial
"Represents settlement of PSUs that vested on March 31, 2026."
PSUs are company shares promised to employees or executives that only become actual stock if the business hits specific performance targets over a set period. For investors, PSUs matter because they link pay to measurable outcomes — similar to a conditional bonus that converts into ownership — which can influence management decisions, dilution of shares, and signals about confidence in future results.
2020 Equity Incentive Plan financial
"pursuant to the Issuer's 2020 Equity Incentive Plan."
vested financial
"Represents settlement of PSUs that vested on March 31, 2026."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did FENC Chief Medical Officer report on this Form 4?
The FENC Chief Medical Officer reported equity awards and vesting activity. He received 120,000 stock options on March 31, 2026, and settled performance share units and restricted shares, increasing his direct common share holdings without any open-market purchases or sales.
How many stock options did the FENC CMO receive and at what price?
The CMO received 120,000 incentive stock options at $5.77 per share. These options were granted on March 31, 2026 and provide the right to purchase FENNEC PHARMACEUTICALS INC. common shares at that fixed exercise price until their expiration in 2036.
What is the vesting schedule for the FENC CMO’s new stock options?
The options vest over roughly two years starting in 2027. One-third vests and becomes exercisable on March 31, 2027, then one twenty-fourth vests on the last day of each following month so that 100% is vested by March 31, 2029.
Were there any open-market buys or sells by the FENC CMO in this Form 4?
No open-market buy or sell transactions are reported. The filing shows a grant of incentive stock options, settlement of performance share units, and release of restricted shares, all of which are compensation-related equity events rather than discretionary market trades.
AI-generated analysis. How Rhea-AI works. Not financial advice.
